Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: Signal pathway and mechanism of MUC1-C regulating TNBC Occurrence and progression (Comprehensive arrangement according to the published articles).

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques:

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: Schematic illustration of MUC1-C shRNA@Fe 3 O 4 MNPs construction and the therapeutic mechanism on TNBC. MUC1-C shRNA and Fe 3 O 4 MNPs were self-assembled into MUC1-C shRNA@ Fe 3 O 4 MNPs by electrostatic adsorption. After entering TNBC cells and under the action of AMF, on the one hand, it induces apoptosis and ferroptosis by targeting MUC1-C, on the other hand, it increases the temperature (43 °C) and the Fe 2+ concentration directly kills TNBC cells and stimulates apoptosis and ferroptosis mechanisms.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: shRNA, Adsorption, Concentration Assay

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( D ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ). IHC results of MUC1 in TNBC tissues, paraneoplastic tissues and normal breast tissues ( F ). Error bars represent means ± SD. **p<0.01, ****p<0.001.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: Expressing

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: Silence efficiency of MUC1-C shRNA on TNBC cell line HCC-70. RT-qPCR ( A ) and Western blot detected the silencing efficiency of MUC1-C shRNA ( B and C ). MUC1-C shRNA (3#) plasmid map ( D ) and target sequence (the highlighted yellow section) ( E ). Error bars represent means ± SD. ****p<0.001.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: shRNA, Quantitative RT-PCR, Western Blot, Plasmid Preparation, Sequencing

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: Characterization of MUC1-C shRNA@Fe 3 O 4 MNPs. Appearance ( A ) and TEM image ( D ) of the prepared MUC1-C shRNA@Fe 3 O 4 MNPs. DSL Size distribution of Fe 3 O 4 MNPs ( B and C ) and MUC1-C shRNA@Fe 3 O 4 MNPs ( E and F ). Tyndall effect of MUC1-C shRNA@Fe 3 O 4 MNPs ( G ). Zeta potential of MUC1-C shRNA@Fe 3 O 4 MNPs ( H ). Encapsulation efficiency at different shRNA/MNPs ratios ( I ). TEM elemental mapping analysis of MUC1-C shRNA@Fe 3 O 4 MNPs ( J ). Raman spectrum of MUC1-C shRNA, Fe 3 O 4 MNPs, and MUC1-C shRNA@Fe 3 O 4 MNPs ( K ). Release profiles of Fe 2+ from MUC1-C shRNA@Fe 3 O 4 MNPs at different pH values with or without AMF ( L ). The heating curves of MUC1-C shRNA@Fe 3 O 4 MNPs with different concentrations (50–250μg/mL) ( M ). Hemolysis test at different concentrations (MUC1-C shRNA@Fe 3 O 4 MNPs) (n=3) ( N and O ). Hemolysis test (200μg/mL, n=3) ( P and Q ). Error bars represent means ± SD. TEM scale bar: 50nm.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: shRNA, Zeta Potential Analyzer, Encapsulation

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: Cellular uptake of NPs. Cellular uptake of MUC1-C shRNA@Fe 3 O 4 MNPs in the HCC-70 cells was observed under a CLSM. Green fluorescence indicates MUC1-C shRNA@Fe 3 O 4 -FITC and blue fluorescence indicates the nucleus ( A ). Investigation of internalization pathway of MUC1-C shRNA@Fe 3 O 4 MNPs in HCC-70 cells in the presence of different endocytosis inhibitors (n=3) ( B ). Error bars represent means ± SD. Scale bar: 50μm. ****p<0.001.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: shRNA, Fluorescence

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: MUC1-C shRNA@Fe 3 O 4 MNPs suppress the migration, invasion, and proliferation in HCC-70 cell lines. Wound healing ( A ), Transwell ( B ), CCK-8 OD 450nm ( C ), and inhibition rate based on CCK-8 ( D and E ). The protein bands ( F ) and quantitative statistical results ( G ) of Bax, cleaved-caspase3, GPX4, NRF2, and FTH1 of HCC-70 cell lines (n=3). Error bars represent means ± SD. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: shRNA, Migration, CCK-8 Assay, Inhibition

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: The in vivo therapeutic effects of the MUC1-C shRNA@Fe 3 O 4 MNPs on TNBC. IR thermal images of TNBC-bearing C-NKG mice with local injection of MUC1-C shRNA@Fe 3 O 4 MNPs (200 µg mL −1 ), or normal saline under AMF (3Kw) ( A ). Images ( B ) and weights ( C ) of xenograft tumors harvested from the mice after various treatments on the 25th day. Tumor volumes ( D ) and Body weight ( E ) growth in mice were measured after different treatments every 5 days within 25 days (n=4). Prussian blue reaction of tumor tissue showing iron staining and tumor necrosis, labeled area was typical necrosis (200x) ( F ). Expression of Bax, cleaved-caspase 3, GPX4, NRF2, and FTH1 in tumor tissues ( G ). Quantitative statistical results according to the protein bands ( H ). Error bars represent means ± SD. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: In Vivo, shRNA, Injection, Saline, Staining, Labeling, Expressing

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: Serum biochemistry indicators assessment of TNBC mice (n=4). Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), Total bilirubin (TBIL). Blood urea nitrogen (BUN), Creatinine (CR) ( A ). Effect of MUC1-C shRNA@Fe 3 O 4 MNPs on the histopathology of heart, lung, spleen, Kidney, and liver from TNBC mice ( B ). Error bars represent means ± SD. Scale bar: 100μm.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: shRNA, Histopathology

Journal: Clinics

Article Title: Cited Brazilian papers in general surgery between 1970 and 2009

doi: 10.1590/S1807-59322010000500010

Figure Lengend Snippet: List of the Brazilian thirty most cited articles in general surgery, during the period of 1970–2009 years.

Article Snippet: 1 , 194 , Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins. , 1991 , Dis Colon Rectum , Cutait R, et al. , USP Hosp Sirio Libanes , Brazil , Cutait R, Alves VA, Lopes LC, Cutait DE, Borges JL, Singer J, da Silva JH, Goffi FS..

Techniques: Immunoperoxidase Staining, Marker, Immunohistochemical staining, Activity Assay, Transplantation Assay, Saline, Dissection, Comparison, Diagnostic Assay, Wilms Tumor Assay, Cell Culture, Irradiation, Modification